Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2021—LGC announced its acquisition of Technopath Clinical Diagnostics, expanding LGC’s position in the clinical diagnostics QC market. Technopath’s chemistry and immunoassay controls will be brought into LGC’s clinical diagnostics business unit.
March 2021—Visby Medical announced FDA authorization of the company’s rapid PCR COVID-19 test for use at the point of care by organizations with a CLIA certificate of waiver.
March 2021—Siemens Healthineers announced the company’s laboratory-based SARS-CoV-2 Antigen Assay obtained the CE mark. The test runs on the Atellica IM analyzer, which has the capacity to run 440 tests per hour, and the Advia Centaur XP and XPT immunoassay systems.
March 2021—Sarstedt introduced the Microvette APT for capillary blood collection. The tubes are available with either a 250-µL or 500-µL maximum fill volume. Both options have 75 × 13 mm external tube dimensions with a false bottom, feature a thin collection rim, are prepared with K2 EDTA, and have a pierceable and leak-resistant cap. The Microvette APT 250 offers a preassembled end-to-end capillary for collection. The Microvette APT 500 has a variable filling volume from 250 to 500 µL.
March 2021—Thermo Fisher Scientific announced the availability of a direct from saliva PCR test for COVID-19 to enable widespread, high-frequency surveillance testing. The Applied Biosystems TaqCheck SARS-CoV-2 Fast PCR Assay Kit is a multiplexed RT-PCR assay for the qualitative detection and characterization of SARS-CoV-2 RNA (S and N genes) plus a human RNAse P assay to help assess sample adequacy. The assays are designed to work with raw saliva from research samples.
March 2021—Seegene announced it has developed the first COVID-19 diagnostic variant test capable of screening COVID-19 and identifying multiple mutant variations in a single reaction.
March 2021—A rapid coronavirus test that provides results for COVID-19 in 39 minutes is available on the Vivalytic, a point-of-care platform by Randox Laboratories and Bosch. The CE-approved test has a sensitivity of 98 percent and a specificity of 100 percent.
March 2021—PerkinElmer launched its PerkinElmer COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens. The lateral flow immunoassay test can be used to screen or to aid in diagnoses of COVID-19 in asymptomatic or symptomatic individuals. A positive or negative result can be obtained in 15 minutes.
March 2021—Parker Isaac Instruments released the Adipress benchtop instrument designed to standardize tissue dissection for cancer staging. Through an automated compressive filtration cycle, the Adipress separates diagnostically irrelevant adipose tissue from underlying lymph nodes, lymphatics, and vasculature. The result is a compressed tissue mass that is 70 to 90 percent reduced in size, allowing for complete submission and microscopic review.
February 2021—Euroimmun launched its CE-marked EuroRealTime SARS-CoV-2/Influenza A/B, which detects and differentiates genetic material from SARS-CoV-2 and influenza virus types A and B using throat swab samples of patients with acute symptoms, which can be indicative of COVID-19 or flu. The assay is compatible with common real-time PCR thermal cyclers and is available in countries that accept the CE mark. The EuroRealTime analysis software allows for standardized evaluation of test results. The company also launched its CE-marked SARS-CoV-2 Antigen ELISA, a laboratory diagnostic test for the direct detection of SARS-CoV-2 by semiquantitative determination of the virus-specific nucleocapsid protein in swab samples from the upper respiratory tract. Validation data revealed 93.6 percent sensitivity and 100 percent specificity as compared with real-time PCR tests. The assay can be automatically processed on all open ELISA platforms and is available in countries that recognize the CE mark.
